Sonnet biotherapeutics announces an agreement with janssen for the evaluation of three sonnet product candidates

Sonnet's three products, son-1010, son-1210 and son-1410 to be evaluated in combination with janssen's cell therapy assets in vitro and in vivo evaluations to be conducted by janssen in preclinical models subject to successful results, sonnet could seek an expanded collaboration princeton, nj / accesswire / october 31, 2022 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn), a clinical-stage company developing targeted immunotherapeutic drugs, announced today a collaboration agreement with janssen biotech, inc. (janssen), one of the janssen pharmaceutical companies of johnson & johnson, where in vitro and in vivo efficacy of son-1010 (il12-fhab), son-1210 (il12-fhab-il15) and son-1410 (il18-fhab-il12) will be evaluated in combination with certain janssen proprietary cell therapy assets. the agreement was facilitated by johnson & johnson innovation.
SONN Ratings Summary
SONN Quant Ranking